Lesinurad and arhalofenate, inhibitors of URAT1 and OAT4, respectively, offer promising therapeutic avenues
Phase 3 clinical results, led largely by the OASIS 4 trial, show that participants who took the pill alongside lifestyle changes achieved an average weight loss of 16-17% after more than a year of treatment - figures that rival those of the injectable version
Clinically, the condition presents primarily with pelvic pain and infertility (3), often coexisting in affected patients
Therefore, patients with inadequate or no insurance coverage may have affordability concerns
Radiological supervision and interpretation IV
Las reacciones adversas se enumeran en orden decreciente de gravedad dentro de cada intervalo de frecuencia